Background: The German multicenter randomized phase II larynx organ preservation (LOP) trial DeLOS-II was carried out to prove the hypothesis that cetuximab (E) added to induction chemotherapy (IC) and radiotherapy improves laryngectomy-free survival (LFS; survival with preserved larynx) in locally advanced laryngeal/hypopharyngeal cancer (LHSCC).
Introduction
Larynx organ preservation (LOP) in locally advanced laryngeal and hypopharyngeal head and neck squamous cell carcinoma (LHSCC) is very desirable, although total laryngectomy (TL) represents an effective treatment strategy. Current treatment options to preserve the larynx and its function include primary concurrent chemoradiotherapy (CRT) or induction chemotherapy (IC) followed by radiotherapy (IC þ RT). The 'VA' trial [1] established IC þ RT utilizing PF (cisplatin, P, plus 5-fluorouracil, F) for IC as appropriate alternative to TL and achieved 35% LOP. Despite verification of this finding, e.g. in the EORTC 24891 trial [2] , IC þ RT is still not accepted, whereas cisplatin-based CRT is still recommended for LOP [3, 4] . Nevertheless, PF-based IC þ RT was superior to CRT by causing less severe late toxicity, and increasing laryngectomy-free survival (LFS) due to fewer non-cancer deaths as shown in the RTOG 91-11 trial [4] . Moreover, CRT was associated with increased late toxicity and impaired survival especially in T4a LHSCC-patients [5, 6] .
The potential need for salvage surgery due to tumor persistence after full per-protocol treatment proved to be a major disadvantage of LOP. Late salvage TL after CRT or radiotherapy causes major complications and is often not feasible [7, 8] . Therefore, early identification of patients unlikely to benefit from LOP attempts is needed to spare the consequences from complete CRT or radiotherapy plus salvage surgery. Since new multimodal treatment protocols and chemotherapies including targeted therapies were emerging [9] , further development of LOP by IC þ RT remained under consideration. TAX 323 [10] revealed IC with TPF, the combination of docetaxel (T) with PF, being superior to PF alone [10] . The GORTEC 2000-01 trial demonstrated superiority of TPF in LOP [11] . The DeLOS-I trial showed efficacy of TP-based (carboplatin plus paclitaxel) IC þ RT with low late dysphagia rates [12] . However, literature is consistent that IC before radiotherapy or CRT prolongs progression-free survival but does not improve overall survival (OS) significantly [13] . The EHNS-ESMO-ESTRO guidelines recommend with evidence level II grade of recommendation A (II A evidence) exclusively TPF-IC followed by radiotherapy in responsive patients as an option for LOP in local advanced LHSCC otherwise requiring TL [14] .
Nearly simultaneous to publication of TAX 323 [10] the humanized antibody cetuximab (E) targeting the epidermal growth factor-receptor emerged as treatment of HNSCC [15] . Therefore, we hypothesized that TPF þ E improves LFS and designed the DeLOS-II trial [16] to study TPF short-IC 6cetuximab (TPF 6 E) to improve patient selection and LOP (supplementary Figure S1 , available at Annals of Oncology online). We present final results of DeLOS-II focusing on 24 months LFS (the primary clinical end point).
Methods

Study design
DeLOS-II is a randomized two-armed (A and B, ratio 1 : 1) phase II LOP trial for confirmatory proof of adequate 24 months LFS (NCT00508664) [16] . Details are provided in supplementary Figure S1 , available at Annals of Oncology online. The primary objective would be met if the lower bound of the two-sided 80% CI is above 35% (supplementary Figure S1 , available at Annals of Oncology online). Secondary objectives included 24 months OS after randomization, 6-and 24 months functional LFS (fLFS), early response after IC-1, toxicity, and complications during and after salvage surgery. The protocol was approved by the ethics committee of the Medical Faculty of the University Leipzig (vote 166-07-12072006).
Treatment
According to the European TPF regimen [10] , docetaxel (75 mg/m 2 ) and cisplatin (75 mg/m 2 ) were sequentially administered on day 1, and 5-FU 750 mg/m 2 days 1-5 i.v. (IC-1). Early response evaluation was carried out after IC-1 to select in week 4 poor-responders for early salvage TL avoiding unnecessary toxic treatment and harmful late salvage TL. Responders were scheduled to receive two further TPF cycles in weeks 4 and 8, followed by radiotherapy starting in week 11 (supplementary Figure S1 , available at Annals of Oncology online). Radiotherapy was predefined as accelerated IMRT with concomitant boost (total dose 69.6 Gy) applied over 5.5 weeks to all tumor localizations; clinically non-affected neck levels received 51.6 Gy. IC in arm B was identically but patients received cetuximab (E) additionally with 400 mg/m 2 loading dose (day 1) followed by 250 mg/m 2 weekly over 16 weeks totally.
Patients
Registered patients providing written informed consent according to the Helsinki Declaration II were random seed-dependent centrally randomized after screening following the protocol-defined workflow to confirm eligibility (full body examination, pan-endoscopy, biopsy in total anesthesia with pictogram and photo documentation for histopathology, head-neck/thorax CT-scan, X-ray esophagus, ultrasound neck and abdomen, dental status, cardiac status, audiometry, basic clinical chemistry, blood count, creatinine clearance).
Early response evaluation and follow-up assessments
After IC-1, early response evaluation was carried out in week 4 under general anesthesia by endoscopic estimation of tumor-surface shrinkage (ETSS). If ETSS !30% was documented and verified by external review (supplementary material, available at Annals of Oncology online), the patient continued with per-protocol-treatment ( Figure 1, left panel) . If ETSS !30% was not achieved, per-protocol-treatment ended and TL recommended. Documentation of surgical complications (after TL and neck dissection) was standardized [7] .
Statistical analysis
All eligible patients receiving IC-1 were included in this report (intentto-treat analysis, ITT). The predefined ITT analyses were done using SPSS version 24 (IBM Corporation, Armonk, NY Table S2 , available at Annals of Oncology online) and therefore allowed continuing the trial. 
Acute toxicity
During IC (weeks 1-10) all study patients had at least one adverse event (AE); 104 (A/B: 45/59) equaling 60.1% (52.9%/67.0%) had at least one severe AE (SAE; G3/G4; Table 2 ). The sum of G5 toxicities was 3 in TPF, 1 in TPFE, 2 in TP and none in TPE (6 patients; deaths clearly related to study medication). Another 4 patients died during IC (3 before, 1 after amendment 2) potentially linked to the study medication (3 TPF, 1 TPE) caused by pulmonary embolism, nephrotoxicity, hepatotoxicity, ischemic gastrointestinal necrosis). Major cetuximab-specific toxicities included significantly myelosuppression and hypomagnesemia, hypocalcemia, and acneiform rash. Supplementary Table S2 , available at Annals of Oncology online compared toxicity categories dependent on IC 6 5-FU. After removal of 5-FU the neutropenia-associated infection rate in the TPE groups dropped significantly to an acceptable low level.
Efficacy
Of 173 ITT patients, 7 (A/B: 6/1) died before early response evaluation (4 therapy-related, 3 other reasons: circulatory failure, pulmonary embolism, and renal failure) and were classified as poorresponders. Week 4 showed 47 (27/20; 27.2%, 31.8%/22.7%) poor-responders; 126 (58/68; 72.8%, 68.2%/77.3%) earlyresponders had ETSS !30%. TL was recommended to all poorresponders; 26 (13/13; 15.0%, 15.3%/14.8%) agreed and had TL. Because of AE, 3 (1/2; 2.4%, 1.7%/2.9%) of 126 early responders scheduled for continuing per-protocol-treatment refused further participation after IC-1 and 3 (4.4%, all B) after IC-2. Including these, 19 (10/9; 11.0%, 11.8%/10.2%) patients discontinued perprotocol treatment during IC and were treated outside DeLOS-II ( Figure 1, right panel) . Four early responders (2/2; 2.3%, 2.4%/ 2.3%) died after IC-2. Finally, 115 early responders (55/60; 66.5%, 64.7%/68.2%) completed per-protocol treatment (3 cycles IC þ RT); 1 had only 2 cycles ICþRT. The mean duration of medical treatment was 10.6 6 7.6 (median 15.4) versus 12.0 6 6.5 (median 15.4) weeks in A versus B. After per-protocol ICþRT, 107 (50/57; 61.8%, 58.8%/64.8%) patients had complete response (CR), 9 (5/4; 5.2%, 5.9%/4.5%) required a protocoldefined neck dissection (Figures 1 and 2 ). ETSS !30% was predictive for CR after ICþRT with odds ratio (OR) of 6.63 (95% CI 4.38-10.04; P ¼ 3.00Â 10
À24
). Thereafter, 116 (55/61) early responders were tumor-free and alive with 67.1% 6 months LFS (64.7%/69.3%; P ¼ 0.628). Hence, ETSS !30% reliably predicted successful completed per-protocol therapy and 6 months LFS (CR after IC þ RT 6 SND: OR 12.6, 95% CI 6.95-22.84; P ¼ 2.21Â 10 À29 ). The primary objective (24 months LFS >35%) was met in arms B (41 patients, 46.6%, 80% CI 39.8% to 53.4%) and A (40 patients, 47.1%, 80% CI 40.1% to 54.0%; P ¼ 0.925 for A versus B). The exploratory log-rank test did not reveal improved LFS in B (P ¼ 0.738; Figure 3A) .
The secondary end points (24 months OS, Figure 3B ; functional LOP, Figure 3C ) were also met. Kaplan-Meier analyses of actuarial freedom from laryngoesophageal dysfunction or persistence of tracheostoma or gastric tube at 24 months (FFLED) censoring death from any cause ( Figure 3D ) also showed no difference between arms (P ¼ 0.828).
Late toxicity
Late toxicity G3/G4 assessed per-protocol after completed therapy (20 weeks) and 6, 12, 18, and 24 months after curative therapy was acceptable (Figure 4 ) and, with weight loss as the only exception, favored arm B (supplementary Figure S2 , available at Annals of Oncology online).
Laryngectomy, tracheostomy, percutaneous endoscopic gastrostomy
Until 24 months, salvage TL was not carried out in 115 (58/57; 66.5%, 68.2%/64.8%) patients. In 51 (22/29; 29.5%, 25.9%/ 33.0%) patients, salvage TL was indicated, feasible and done. Perprotocol, TL was planned for 37 poor-responders (ETSS <30% in week 4; 21.4%). Only 27 (57.4%) poor-responders (14/13; 16.5%/14.8%) agreed; 1 of them (A) died before TL. The mean time from response evaluation to early-salvage TL was 0.5 months (median 0.4). In 13 (9/4; 7.5%, 10.6%/4.5%) poorresponders TL was not done against recommendation. These poor-responders and 3 (1/2) early responders who withdrew informed consent received treatment outside the DeLOS-II protocol and had unfavorable outcome ( Figure 1 , right panel). 7 (2/5) of 16 (10/6) of these patients had LOP at 6 months; only 3 (2/1; 1/1 CRT, 1/0 radiotherapy) achieved 24 months LFS.
Mean time to late salvage TL in early responders with recurrent disease was (A versus B) 10.9 6 6.2, median 9.5, versus 11.8 6 5.3, median 12.4 months. Three (2/1) patients lost function of their larynx due to dysphagia, not a cancer-related event or TL.
Complication rate after TL was acceptable. For 33 (15/18, 62.2%/62.1%) patients neither pharyngo-cutaneous fistulas nor other relevant complication were reported. Sixteen patients developed percutaneous fistula postoperatively. All together nine (4/5, 18.2%/17.2%) patients required a reconstruction with pectoralis major flap. Complication rate in poor-responders who had early salvage TL was lower: only 2 (3.9%) versus 7 (13.7%) late salvage TL-patients required flap reconstruction (no differences between study arms). Neither additional cetuximab nor TP 6 5-FU was associated with salvage treatment complications.
Seventy-seven of the 173 (44.5%) patients had a tracheostomy before (21; 12.1%), during or after treatment (56; 32.3%); tracheostomy was required before definitive TL in 18/51 (35.3%) laryngectomized patients. Sixty-nine patients including 38 patients with tracheostomy had a gastric tube. Most not-laryngectomized but tracheostomized patients had removal of tracheostomies during follow-up. The persistence of either tracheostomy (6/3) and/or gastric tube (6/5) at 24 months in 15/81 (7/8; 18.5%, 17.5%/19.5%) patients with 24 months LFS, however, led to classification as 'no functional LOP'.
Discussion
The DeLOS-II trial met its primary objective of 24 months LFS >35% in arm B. Cetuximab given concomitantly over 16 weeks during IC þ RT achieved 24 months LFS in 41 patients (46.6%, 80% CI 39.8% to 53.4%), whereas 40 patients in A had 24 month Table 2 . AEs, serious AEs (SAE) according to common terminology criteria for AEs (NCI-CTCAE) Version 3.0 (U.S. Department of Health and human services, National Institutes of Health, National Cancer Institute) in therapy arms diagnosed during treatment, discriminated for induction-chemotherapy (IC) and radiotherapy Comparing the DeLOS-II-with RTOG-91-11 trial-results [4] is difficult as RTOG-91-11 recruited lower stages (64%-67% stage III; only 28.3% in DeLOS-II) and laryngeal cancer exclusively. Nevertheless, the 2-year OS (76% PF-induction, 74% CRT, 75% radiotherapy) in RTOG-91-11 was similar to DeLOS-II (74%). We suggest that the appreciably high OS observed in DELOS-II is attributable to the study-rules, especially earliest possible selection (ETSS).
Predictive validated biomarkers outside clinical and radiologic characteristics are missing. So far, only induction chemotherapy, preferably with TPF, allows for early identification of responders and is predictive for outcome after subsequent radio-or radiochemotherapy [17] [18] [19] . The GORTEC 2000-01 trial showed after IC in advanced LHSCC similar 2-year OS in both PF-and TPF-IC but revealed significant improved LOP after TPF versus PF (73% versus 57%) [11] . Classical imaging (RECIST) after 3 ICcycles defined TL for 19/110 (17.3% TPF) versus 41/103 (39.8% 
During chemotherapy: week 1 to week 10 (T: docetaxel; P: cisplatin; F: 5-fluorouracil; E: cetuximab).
b
Only CTCAE AEs grade 1 or 2 diagnosed in !20% of patients in one arm during IC or RT are shown. Early response evaluation in week 4 (A) used endoscopic tumor surface shrinkage (ETSS) !30% as criterion for partial response as prerequisite for further per-protocol treatment (two further cycles IC followed by radiotherapy with 69.6 Gy), whereas overall response after full per-protocol treatment (B) was evaluated using CT-based imaging according to RECIST 1.1.
PF) non-responders, respectively. The TREMPLIN-trial, combining 3 TPF-cycles with additional randomization for chemo-(cisplatin) or bio-radiation (cetuximab), also selected after IC and recommended 23/153 (15%) patients for TL [20] . Corresponding to earlier tumor stages (only 32% T4a) in the subsequently randomized IC responders, 2-year OS was >80%, and compared with DeLOS-II higher in both groups; LFS after 18 months was 85% [20] . In accordance to retrospective observations from Timmermans [21] and Grover [5] , and revealed by subgroup analyses of DeLOS-II [22] , TL improves OS in T4a laryngeal cancer in comparison to non-surgical treatment. Our data suggest that early outcome prediction by ETSS could achieve successful LOP in selected T4a tumors also, including hypopharyngeal cancer [22] . In DeLOS-II, early response evaluation utilizing the ETSS !30% criterion allowed for selection of responders potentially benefiting from LOP attempts in week 4. This new response monitoring was also evaluated by Fietkau et al. [23] . Both, the Fietkau and the DeLOS-group (including our radiology imaging experts) experienced this endoscopic assessed tumor surface shrinkage with cut-off 30% as reliable and feasible in daily routine setup. Both groups refuse any imaging (RECIST) due to sometimes only critically measurable changes after one cycle IC [22, 23] .
The concurrent administration of cetuximab during IC and radiotherapy was feasible. Cetuximab increased number and severity of AEs (e.g. acneiform rash) but not lethal events (Table 1) . A higher response of primary lesions and neck nodes in B was evident by higher early response rate to IC-1 according to the ETSS !30% criterion and the higher overall response rate after ICþRT (Figure 2 ) that resulted in improved 6 months LFS ( Figure 3A) Figure 3 . Kaplan-Meier analyses per study arm of (A) laryngectomy-free survival (LFS), the primary clinical end point in DeLOS-II, and the secondary end points (B) OS; (C) survival with functional larynx (fLFS) coding persistence of tracheostoma or gastric tube at 24 months; (D) actuarial freedom from laryngoesophageal dysfunction coding loss of larynx and/or larynx function or persistence of tracheostoma or gastric tube at 24 months (FFLED) censoring death from any cause. P values for differences between treatment arms are from log rank tests.
laryngectomy-free interval (LFI) according to Timmermans et al. [21] , that is LOP in responders by censoring death events, the mean LFI would have been 20.7 (95% CI 19.1-22.4) versus 19.5 (95% CI 17.8-21.2) months in A versus B (P ¼ 0.332), and the 24 month LFI rates were 85.5% and 71.7%, respectively. Given the follow-up of only 24 months, these numbers are hardly comparable with retrospectively obtained 10-year data from Timmermans et al. [21] .
Based on the lower IC-related mortality in B and especially the substantially lowered number of fatal events after amendment 2, the initially observed high IC-related death rate was suggested to be linked to 5-FU toxicity in the three-and four-drug regimens (Table 2; supplementary Table S1 , available at Annals of Oncology online). Omission of 5-FU was not associated with an essential loss in efficacy regarding study end points.
The landmark paper by Lefebvre and Ang [24] recommended patient selection as key to success in LOP and focusing on tumor extend (only T2-3), age (<70 years), and defined the end point 'laryngoesophageal dysfunction-free survival' [24] . Except the TREMPLIN-trial [20] all former LOP trials ignored this relevant functional aspect by reporting survival data with larynx in place only. The DeLOS-II trial revealed good functional outcome and low late G3/G4 toxicity ( Figures 3 and 4) , comparable to DeLOS-I [12] . Therefore, IC þ RT according to the DeLOS-II protocol can be recommended based on oncological outcome but also based on preserved larynx function and low late toxicity, especially dysphagia (Figure 4 ; supplementary Figure S2 , available at Annals of Oncology online).
In conclusion, both early response and 24 months LFS compare very well to previous LOP trials and recommend effective treatment selection and stratification by ETSS. Despite being accompanied by an elevated frequency in AEs, the IC with TPF/ TP plus cetuximab was feasible but showed no superiority to IC with TPF/TP regarding LFS and OS. around Burkhard Deuss, Swantje Held and all study nurses of the participating hospitals. We especially thank Tobias Lehmacher and Jeltje Schulten (Merck) for continuing discussions. 
